A prospective, multicenter, real world study: Almonertinib mesilate tablets for EGFR Positive locally advanced or metastatic Non-Small Cell Lung Cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040853

Enrollment

Unknown

Registered

2020-12-11

Start date

2020-10-01

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Almonertinib treatment group:Non-intervention study

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From October 1, 2020 to May 1, 2022 1.Non small cell lung cancer confirmed by histology or cytology; 2.Patients who were treated with almonertinib; 3.Understand and sign the informed consent of the patient and the legal representative.

Exclusion criteria

Exclusion criteria: 1.Those who have been proved to be allergic to almonertinib mesylate tablets and / or its excipients; 2.Using the third generation EGFR TKIs drugs before enrollment; 3.Pregnant or lactating women; 4.Patients with contraindications of almonertinib were excluded; 5.Doctors think it is not suitable to be included.

Design outcomes

Primary

Measure	Time frame
Security;Objective remission rate;	—

Secondary

Measure	Time frame
Progression free survival;Disease control rate;	—

Countries

China

Contacts

Public ContactShen Bo

JiangSu Cancer Hospital

Shenbo987@126.com+86 13913910555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026